JPRN-jRCTs052180193
Active, not recruiting
Phase 4
ShorT and OPtimal duration of Dual AntiPlatelet Therapy-2 study for patients with ACS - STOPDAPT-2 ACS
Ono Koh0 sites3,000 target enrollmentMarch 26, 2019
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Ono Koh
- Enrollment
- 3000
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Patients who have undergone PCI with the everolimus\-eluting cobalt\-chromium stent (CoCr\-EES, XienceTM) in the setting of ACS (STEMI, NSTEMI, or UA) and have not experienced major complications (death, MI, stroke, or major bleeding) during hospital stay for treatment
- •2\) Patients who are capable of oral dual antiplatelet therapy consisting of aspirin and a P2Y12 receptor antagonist
Exclusion Criteria
- •1\) Patients requiring oral anticoagulants
- •2\) Patients with medical history of intracranial hemorrhage
- •3\) Patients who have experienced serious complications (MI, stroke, and major bleeding) during hospital stay post\-PCI
- •4\) Patients with DES other than Xience implanted in PCI performed at the time of enrollment.
- •5\) Patients with coronary bioabsorbable vascular scaffolds (BVS) implanted prior to or at the time of enrollment (including implantation cases in clinical trial)
- •6\) Patients confirmed to have no tolerability to clopidogrel before enrollment
- •7\) Patients requiring continuous administration of antiplatelet drugs (PDE3 inhibitors, prostaglandin preparations, etc.) other than aspirin and P2Y12 receptor antagonists (prasugrel, clopidogrel, and ticlopidine) at the time of enrollment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
ShorT and OPtimal duration of Dual AntiPlatelet Therapy studycoronary artery diseaseJPRN-UMIN000008878Kyoto University Hospital1,500
Active, not recruiting
Phase 4
ShorT and OPtimal duration of Dual AntiPlatelet Therapy-3 studyIschemic heart disease, stable angina, myocardial infarctionJPRN-jRCTs052200114Ono Koh6,000
Active, not recruiting
Phase 1
Optimal duration of dual anti-platelet therapy in patients undergoing endovascular revascularization of the superficial femoral artery.Patients with diagnosis of lower limbs PAOD, ranging from stage 2 to 5 according to Rutherford classification and lesions of the SFA treated by endovascular revascularizationMedDRA version: 20.0Level: LLTClassification code 10016430Term: Femoral artery stenosisSystem Organ Class: 100000004866Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2018-000532-94-ITFONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO78
Active, not recruiting
Not Applicable
Optimal duration of dual antiplatelet therapy after stent-assisted coiling of unruptured intracranial aneurysms: A prospective randomized multicenter trialDiseases of the circulatory systemKCT0006651Seoul National University Bundang Hospital528
Recruiting
Not Applicable
DURATIODiseases of the circulatory systemKCT0004407Seoul National University Bundang Hospital4,748